BioLamina will use the EIB financing to expand and scale up production of its laminins, unique proteins used to grow and maintain cells in laboratory environments, it states. BioLamina’s technologies are used by academic researchers, biotechnology companies and large pharmaceutical organisations across the world.

These advances will strengthen the European Union’s position in life sciences and regenerative medicine.

Backed by the InvestEU programme, the EIB financing will help the company optimize its manufacturing processes, expand its product portfolio, reinforce its technological base and bolster business growth. These advances will strengthen the European Union’s position in life sciences and regenerative medicine.

“Europe needs to turn scientific excellence into global companies,” said EIB Vice-President Karl Nehammer. “By supporting BioLamina’s growth, we are helping ensure that cutting-edge innovation in life sciences can scale in Europe, creating jobs, strengthening competitiveness and ultimately improving public health.”

Venture debt

The EIB loan is in the form of venture debt, a type of long-term financing for innovative, fast-growing companies that complements venture capital and other equity investment while limiting immediate dilution for existing shareholders. The EIB uses venture debt to help companies scale operations and extend their funding runway.

“Cell therapies are rapidly moving from scientific promise to clinical reality, but scaling the production of high-quality cell products remains a fundamental challenge,” said BioLamina CEO Klaus Langhoff-Roos. “This financing allows us to expand our technology and manufacturing capabilities at a critical time, supporting more reliable and scalable development of next-generation therapies.”